Physician profile
Michael E Kupkowski
NPI 1598081598
$3,792.43
in general payments reported to CMS, 2019-2025
25 companies · $912 in 2025
The $912 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,011 · 2024: $870 · 2025: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,792.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $789.48 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Viiv Healthcare Company | $731.70 | 2023-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $726.98 | 2023-2025 | Biktarvy |
| Lilly USA, LLC | $406.03 | 2023-2025 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $362.20 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $211.01 | 2023-2025 | Pifeltro, Delstrigo, Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.58 | 2023-2024 | Xifaxan, Trulance |
| Ardelyx, INC. | $82.69 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $45.80 | 2023-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $39.97 | 2023 | Rexulti, Abilify Maintena |
| Uswm, LLC | $30.64 | 2023 | Zimhi, Lucemyra |
| Amgen INC. | $26.92 | 2024 | Krystexxa |
| Exact Sciences Corporation | $24.11 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $23.27 | 2025 | |
| Lundbeck LLC | $20.02 | 2023 | Rexulti |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $19.25 | 2025 | Flucelvax, Fluad |
| Hologic Sales and Service, LLC | $19.14 | 2023 | Thinprep 2000 Processor, Aptima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.72 | 2023 | Jardiance |
| Abbott Laboratories | $18.64 | 2025 | Freestyle Libre 3 |
| Emd Serono, INC. | $17.99 | 2025 | |
| Idorsia Pharmaceuticals US INC | $16.34 | 2023 | Quviviq |
| Phadia US INC. | $15.73 | 2024 | Immunocap |
| Kowa Pharmaceuticals America, INC. | $15.59 | 2025 | Zoryve |
| Napo Pharmaceuticals INC | $13.38 | 2023 | Mytesi |
| Lucid Diagnostics INC. | $13.25 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kupkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.